Kornimate/medical-research-clean huggingface dataset:
evaluation of the effectiveness of therapy for patients with covid-19 using food supplements viusid + asbrip

Conditions: Covid19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; Viral Infection; Respiratory Tract Infections; Infection, Coronavirus; SARS-CoV2 Infection

Summary: this is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of viusid plus asbrip in patients with mild and moderate symptoms of respiratory illness caused by coronavirus 2019 infection.

this is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of viusid plus asbrip in patients with mild and moderate symptoms of respiratory illness caused by coronavirus 2019 infection. a total of 80 subjects will be randomized 2:1 in this study. 50 patients will be assigned to receive daily oral doses of 4,5 g of viusid every 12 hours and 10 ml of asbrip every 12 hours and standard care with antivirals or not. other 30 patients will be assigned to receive only standard care. treatment duration: 21 days objective of the study: to increase the effectiveness of therapy for patients with covid-19 using food supplements viusid and asbrip. research objectives: 1. to assess the clinical symptoms of covid-19 in patients on the background of combination therapy with the inclusion of food supplements viusid + asbrip. 2. to investigate the dynamics of indicators of laboratory diagnostics against the background of complex therapy with the inclusion of food additives viusid + asbrip in the complex treatment of covid -19. 3. to study the dynamics of indicators of instrumental methods of treatment. 4. to develop an algorithm for the management of patients with coronavirus infection in order to increase the effectiveness of therapy and rehabilitation of patients with this pathology.

Eligibility criteria:
the eligibility criteria for inclusion in the study were as follows: * male and female hospitalized patients who have signed an informed consent. * aged between 18-85 years old. * rt-pcr confirmed covid-19. * fever (over 37.2 celsius degrees). * ct scan percentage area of lung involvement with ground-glass opacities \< 50 %. * respiratory rate \< 20-30 /min * spo2 ≥ 95%. the exclusion criteria were as follows: * oxygen support (ventilation and non-invasive) * uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings. * any known intolerability to any of the study regimens' components. * patient's family or official relations with a member of staff of the clinical site. * patient's failure to assess his/her physical and/or emotional condition. * patient's failure to comply with the study requirements. * patient's refusal to participate in the study. * pregnancy or breastfeeding.

Keywords: covid-19 supportive care immuno-modulator antiviral symptoms relieve
innovations in genicular outcomes registry

Conditions: Knee Osteoarthritis

Summary: the registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (oa) or pain optimization for knee arthroplasty due to knee oa. the oa pain therapies may include cryo nerve block, radiofrequency ablation (rfa), intra-articular (ia) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[nsaids\]).


Eligibility criteria:
inclusion criteria: 1. planned to receive treatment for knee oa pain including, but not limited to, knee injections, nerve blocking procedures, or knee arthroplasty within 60 days of screening 2. able to understand the informed consent and assessment questionnaires and have the ability to complete them in the opinion of the investigator 3. have access to a smartphone or internet access with a computer/tablet to complete the questionnaires using the registry application exclusion criteria: 1. actively enrolled in an investigational trial that would preclude patients from receiving the site's standard of care for knee oa pain or knee arthroplasty recovery protocol 2. planning to have a surgery other than on the target knee
clinical study of safety and efficacy for the relieva stratus with elution of triamcinolone acetonide

Conditions: Sinusitis

Summary: study design: a non-randomized, multi-center, prospective, clinical study intended to evaluate the safety and efficacy of treating the ethmoid sinuses with the ethmoid sinus spacer and access system used for the local delivery of triamcinolone acetonide, over a period of 28 days.


Eligibility criteria:
inclusion criteria: * male or female subjects age 17 years or older * radiographic evidence of ethmoid disease (baseline ct scan obtained within 30 days of scheduled surgery) * diagnosis of chronic sinusitis and failed medical management (minimum of 3 weeks of antibiotics) exclusion criteria: * age \< 17 years old * history of glaucoma or diagnosis of glaucoma (baseline visual exam indicating iop \>21 mmhg) * adequate anatomical distances for treatment * patient received oral steroid treatment within two weeks prior to day of surgery * radiographic evidence of extensive sinonasal osteoneogenesis which could prevent device placement * sinonasal tumors or obstructive lesions * history of facial trauma that distorts sinus anatomy and precludes access to the ethmoid sinus * contracted/underdeveloped ethmoid sinus * dehiscent lamina orbitalis * previous ethmoid surgery * ethmoid mucocele * extensive nasal polyps * asthmatic patients with aspirin sensitivity * pregnant or lactating females
bilateral dual tap block: description of a novel four-point approach

Conditions: Postoperative Pain

Summary: a prospective study of 30 patients with severe postoperative pain following abdominal surgery, in which the dual tap block technique has been used successfully to achieve pain relief. a description of ultrasound technique, effectiveness, duration and potential side effects of the pain treatment, with possible recommendations for future use.

this prospective cohort study is designed to describe a novel ultrasound-guided bilateral dual transversus abdominis plane (bd-tap) block and to evaluate the postoperative analgesic efficacy in a selection of patients having undergone major abdominal surgery under general anaesthesia where neuraxial anaesthesia and/or intravenous administration of analgesics had failed or was unwanted by the patient, or if the placement of an epidural catheter was deemed impossible by the anaesthetist in charge. 30 consecutive patients planned for the study. bd-tap to be performed bilaterally with a high frequency linear ultrasound probe, with bupivacaine. success rate, decline in vas score, postoperative demand of opioids and block performance time to be recorded.

Eligibility criteria:
inclusion criteria: * patients with pain vas \>5 following abdominal surgery, in which conventional pain treatment or epidural block is either ineffective or contraindicated exclusion criteria: * hypersensitivity to local anaesthetics

Keywords: postoperative pain abdominal surgery bilateral dual tap block
carotid artery stenting with cilostazol addition for restenosis

Conditions: In-stent Restenosis After Carotid Artery Stenting

Summary: cas-care study was conducted to evaluate the inhibitory effect of cilostazol, compared to that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting (cas) in patients scheduled to undergo cas. study design is multicenter prospective ranodomized controlled study, rondomized by cilostazol/non-cilostazol group prior to cas. 900 patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after cas, evaluated by carotid ultrasound and angiography.

restenosis after carotid artery stenting (cas) is a critical issue. cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. the investigators confirmed and published periprocedural cilostazol administration reduced incidences of in-stent restenosis (isr) or target vessel revascularization (tvr) after cas, retrospectively. cas-care study is multicenter prospective ranodomized controlled study. patients, scheduled for cas within 30 days, 50% or more symptomatic carotid stenosis or 80% or more asymptomatic carotid stenosis, will enroll and randomize by cilostazol/non-cilostazol group. 900 patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after cas, evaluated by carotid ultrasound and angiography. and, evaluate cardiovascular events, including stroke, myocardial infarction, and hemorrhagic events in periprocedural period and followed period. in this study, isr is diagnosed by ultrasound and dsa/cta. equivalence of cta to ultrasound will be studied.

Eligibility criteria:
inclusion criteria: * 50% or more symptomatic carotid artery stenosis or 80% or more asymptomatic carotid artery stenosis * scheduled for carotid artery stenting within 30 days * 45 or more years-old and less than 80 years old * antiplatelet agents can be administratered orally * follow-up is anticipated possible for 2 years after cas * self-supporoted in daily activities (modified rankin scale 2 or less) * patients who have given informed consent to participation in the study exclusion criteria: * received endovascular interevention * scheduled for bilateral carotid intervention * aortitis or cvasculitis * congessive heart failure * ischemic stroke within 48 hours * hemorrhagic stroke within 90 days * renal failure

Keywords: carotid artery disease carotid artery stenting in stent restenosis cardiovascular event intima media thickness
cerebral amyloid imaging using florbetapir (av-45)

Conditions: Dementia; Cognition Disorders

Summary: this study is aimed at examining the interest of amyloid radiotracer florbetapir (18f-av-45) for the etiological diagnosis of poststroke cognitive impairment and dementia

this study is aimed at examining the interest of amyloid radiotracer florbetapir (18f-av-45) for the etiological diagnosis of poststroke cognitive impairment and dementia. this study stems from two converging objectives: (1) the need to refine characteristics of vascular cognitive impairment (vci) and dementia (vd) in order to propose diagnosis criteria of vci and of mixed dementia and to improve diagnosis criteria of vd and (2) the need to improve the etiological diagnosis of poststroke cognitive impairment and dementia. it will take advantage from the ongoing grecog-vasc study (which determines the cognitive status 6 months poststroke in consecutive patients according to a standardized international battery) coordinated by the amiens university hospital center, the opportunity to perform amyloid imaging in vivo using positron emission tomography (pet) and florbetapir (a production site is located in the city of amiens) and the collaboration between neurology and imaging departments of amiens university hospital.

Eligibility criteria:
inclusion criteria: 1. patients suffering of parenchymal stroke visualized by imaging (mri), 2. patients suffering from cognitive impairment on the 6 months assessment (including grecogvasc patients), 3. age between 40 and 80 years, 4. french-speaking, 5. reliable informant, 6. agreeing to participate in the study, 7. affiliation to a social security system, exclusion criteria: 1. women of childbearing potential (defined as pre-menopausal, less than 2 years postmenopausal, or not surgically sterile), or who are breast-feeding 2. history of relevant severe drug allergy or hypersensitivity, 3. patient receiving any investigational medications at least in the 30 last days, 4. stroke affecting the cerebellum, 5. mental retardation, 6. illiteracy, 7. dementia diagnosed before stroke, 8. history of schizophrenia or psychiatric illness requiring a stay for \> 2 days in a psychiatry unit, 9. persons placed under judicial protection, 10. comorbidities affecting cognition (respiratory, renal, liver, heart failure), 11. persistent disturbance of consciousness defined by a score to item 1a of the national institute of health stroke scale (nihss) ≤ 1, 12. contraindication to mri.

Keywords: cerebral amyloid imaging florbetapir 18f-av-45 poststroke
the best dose of esketamine for day surgery of pediatric circumcision pediatric circumcision

Conditions: Phimosis

Summary: in recent years, daytime operation has been developed gradually in china. circumcision in children is a common type of daytime operation. the nature of the operation and the object of the operation determine that the anesthetic drugs used should induce fast, wake up quickly and recover in a high quality. esketamine is an s-enantiomer of ketamine, which is newly marketed in china. compared with ketamine, it has stronger effect on nmda receptor, and its sedative effect is about twice as high. the occurrence frequency of respiratory depression and hypotension is lower than that of other anesthetics and analgesics, which can provide good analgesic and sedative effect for surgical anesthesia. in clinical practice, ketamine combined with sevoflurane has been widely used in children's microsurgery, but there has been no report on esketamine combined with sevoflurane anesthesia. in order to find out the best combined dose, this paper compares the single administration of three different doses of esketamine combined with sevoflurane anesthesia in the circumcision of children.

to investigate the optimal dose of esketamine combined with sevoflurane for pediatric circumcision. methods children who underwent day surgery of pediatric circumcision were randomly divided into 3 groups according to the random number table method:0.5mg/kg esketamine group (group a), 0.75mg/kg esketamine group (group b) and 1.0mg/kg of esketamine group (group c), with 30 people in each group. mask inhalation of sevoflurane anesthesia, each group was given a single intravenous dose of the corresponding esketamine. heart rate (hr), mean arterial pressure (map), pulse oxygen saturation (spo2) and respiratory rate (rr) were recorded at room entry (t0), intravenous ketamine administration (t1), operation initiation (t2), intraoperative central ligation (t3) and operation completion (t4).the number and total amount of ketamine added intraoperatively were recorded. duration of operation, time to open eyes and time to answer were recorded. the eastern ontario children's hospital pain score (cheops score) and the modified bieri pain score were recorded when awake, 2 hours and 6 hours postoperatie. moaa/s score was recorded at 15, 30 and 60min after surgery. intraoperative and post-operative adverse reactions were recorded, including hypersensitivity, agitation, nausea and vomiting, dizziness, diplopia, etc.

Eligibility criteria:
inclusion criteria: * phimosis exclusion criteria: * cardiopathy * asthma * dysgnosia * surdimutism * hepatopathy or nephropathy

Keywords: esketamine sevoflurane children circumcise
efficacy and tolerability of lubiprostone in patients with nonalcoholic fatty liver disease

Conditions: NAFLD

Summary: objectives to evaluate the efficacy, safety, and tolerability of lubiprostone in patients with nonalcoholic fatty liver disease (nafld). this study will include 100 patients with nonalcoholic fatty liver disease (nafld) recruited from the specialized nafld outpatient's clinic in national hepatology and tropical medicine research institute (nhtmri). study design: randomized controlled trial.


Eligibility criteria:
inclusion criteria: - 1. age from 18-65 years. 2. cases with nafld suspected by abdominal ultrasound or ct. 3. negative viral hepatitis markers (hepatitis b surface antigen \&hepatitis c virus antibody). 4. negative autoantibodies (antinuclear antibody). 6. non-cirrhotic patients as diagnosed by fibroscan (f4\ 5% with mri-pdff. exclusion criteria: * 1. history of other forms of liver disease (including viral hepatitis, autoimmune hepatitis, hemochromatosis, wilson's disease, and alpha-1-antitrypsin disease). 2. alcohol intake exceeding 30 g/day in the last 10 years or exceeding 10 g/day in the previous year (saunders et al., 1993). 3. child-pugh score \> 7. 4. cirrhotic patients diagnosed by fibroscan (f4\>14.6kpa) 5. calculated estimated glomerular filtration rate (egfr) \<60 ml/min/1.73m2. 6. pregnancy. 7. evidence of hepatocellular carcinoma as stated by barcelona clinic liver cancer (bclc) (llovet et al., 2003). 8. contraindications to mri: prostetic heart valves and annuloplasty rings, metallic implants, patients who have peacemaker, and contrast allergy.
a study of lnk01001 capsule in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the objective of this study was to evaluate the safety and efficacy of multiple doses of lnk01001 monotherapy versus placebo in the treatment of adults with active ankylosing spondylitis

this study includes two periods. in period 1, participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral lnk01001 dose a or lnk01001 dose b or a matching placebo for 12 weeks. participants who receive a placebo in period 1 will be re-randomized at week 13 in a 1:1 ratio to receive a twice daily oral lnk01001 dose a or lnk01001 dose b for 12 weeks (period 2). those participants, based on the asas40 response, who receive lnk01001 (dose a or dose b) in period 1 may switch to receive a different treatment dose for 12 weeks (period 2).

Eligibility criteria:
inclusion criteria: * participants between ≥ 18 and ≤75 years of age. * diagnosis of ankylosing spondylitis (as) who meet the 1984 revised new york criteria for as. * subjects must have disease activity at screening and baseline visit. * subjects have received nsaids treatment but still have active as, or subjects have an intolerance to or contraindication for nsaids. * never received tumor necrosis factor alpha (tnfα) treatment or prior exposure to ≤1 before randomization. exclusion criteria: * history of infection or any active infection. * history of malignancy or current diagnosis of malignancy within 5 years before screening visit. * previous recipient of an organ transplant. * diagnosis of active uveitis within 6 months before randomization. * subject with any major surgery (including joint surgery) within 3 months before randomization or planned major surgery within the first 6 months during study. * prior exposure to janus kinase (jak) inhibitor. * subjects who are allergy to any component of the study drug.
effect of papaverine on renal artery blood flow volume

Conditions: Kidney Cancer

Summary: the purpose of this study is to evaluate the effect of papaverine on renal artery blood flow after declamping of renal artery.

the purpose of this study is to evaluate the effect of papaverine on renal artery blood flow after declamping of renal artery in patients undergoing robot assisted partial nephrectomy.

Eligibility criteria:
inclusion criteria: * patients diagnosed with kidney cancer. * patients undergoing robot assisted partial nephrectomy under general anesthesia * 20 years old ≤ age \<80 years old * patients who voluntarily agreed to this clinical study * egfr ≥ 60 ml / min / 1.73 m2 (chronic kidney disease epidemiology patients with collaboration) exclusion criteria: * the tumor ≥ 7 cm in size * multiple renal mass * if the surgery plan is changed due to open * when surgery is performed together with other surgery * multiple renal artery * patients with hypersensitivity to papaverine * patients with atrioventricular block * pregnant and lactating women * patients using levodopa * refusal of patient
elesclomol (sta-4783) with paclitaxel versus paclitaxel alone in melanoma

Conditions: Melanoma

Summary: "elesclomol (sta-4783), n-malonyl-bis (n'-methyl-n'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. sta-4783 induces an oxidative stress response in cells. this response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals. subjects will participate in up to 2 weeks of screening during which time they will complete all screening procedures. eligible subjects who have not received any prior cytotoxic chemotherapeutic agent for melanoma will be randomized in a 1:1 ratio to receive either sta-4783 213 mg/m2 in combination with paclitaxel 80 mg/m2 or paclitaxel 80 mg/m2 alone. one treatment cycle will consist of weekly treatments for 3 weeks, followed by a 1-week rest period. cycles will be repeated every 4 weeks until disease progression. tumor assessments will be performed every 8 weeks from the date of randomization or sooner if the investigator suspects progression has occurred based on clinical signs and symptoms. "


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic (stage iv) melanoma of cutaneous origin * ecog performance status of \<=2 * measurable disease according to modified recist * life expectancy of greater than 12 weeks * ldh \<= 2.0 x uln * clinical lab values within protocol parameters. * at least 18 years old and able and willing to provide informed consent to participate exclusion criteria: * previous cytotoxic chemotherapy treatment for melanoma * received more than one regimen of immunotherapy, kinase inhibitor, biologic therapy, vaccine or investigational non-chemotherapeutic treatment for melanoma. * presence of brain metastases * presence or history (\<= 5 years) of a second malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ * female subjects who are pregnant or nursing

Keywords: melanoma oncology stage iv metastatic melanoma
self-regulation for older adults with asthma through remote education

Conditions: Asthma

Summary: this research is studying whether changing an individual's behaviors may have an impact as a treatment or outcome for asthma. the purpose of this study is to implement and evaluate an asthma self-management intervention through multiple locations in the united states that is tailored to the challenges older adults face and is based on an individual behavioral theory of change. eligible participants will be enrolled and participate for six weeks in the soar intervention.


Eligibility criteria:
inclusion criteria: * physician diagnosis of asthma * poorly controlled asthma, as evidenced by a score ≤ 19 on the asthma control test * have a primary care provider willing to participate in the study by receiving email updates regarding the status of the participant exclusion criteria: * physician diagnosis of any other significant cardiopulmonary disease (including chronic obstructive pulmonary disease) * a greater than 20 pack-year smoking history * lack of telephone access * decreased cognitive capacity such that participation in the program would not be possible

Keywords: asthma education self-regulation remote education counseling